MedTrace Logo

Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease

NCT07175922 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-02-19

No results posted yet for this study

Summary

This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.

Conditions

  • Parkinsons Disease (PD)

Sponsors & Collaborators

  • Vertero Therapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-25
Primary Completion
2026-03-30
Completion
2026-03-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07175922 on ClinicalTrials.gov